Navigation Links
MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
Date:2/14/2008

GERMANTOWN, Md., Feb. 14 /PRNewswire-FirstCall/ -- MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced that it has engaged Morgan Stanley as its strategic advisor in connection with the Company's ongoing process to explore strategic alternatives.

As previously announced, in 2007, MiddleBrook's board of directors authorized the Company to evaluate various strategic alternatives to further enhance shareholder value. Since that time, MiddleBrook has been involved in the process of evaluating a full range of strategic alternatives available to the Company. Pacific Growth Equities, LLC will act as co-advisor with Morgan Stanley in MiddleBrook's ongoing strategic process.

Strategic alternatives the Company may pursue could include, but are not limited to, continued execution of the Company's operating plan, the sale of Company assets, partnering or other collaboration agreements, or a merger, sale of the Company or other strategic transaction. There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive terms. The Company does not intend to disclose developments with respect to this process unless and until the evaluation of strategic alternatives has been completed.

ABOUT MIDDLEBROOK PHARMACEUTICALS:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq:
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management
2. MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results
3. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)...t. 6 /PRNewswire/ -- Developed in collaboration wi...ades, CA is introducing,Revolutionary Breast Surfa...c Surgery office of Dr. Steve Laverson this week i...he first of its kind, and is based on,breakthrough...with,innovative proprietary software. The XS-300(T...
(Date:10/6/2008)...ct. 6 /PRNewswire/ -- The organizers of Informex a...e on Global Sourcing for the,Pharmaceutical Indust...inceton Marriott in New Jersey USA., The conferen... the,Global Sourcing Council, and boasts an unpara...e likes of Johnson & Johnson, Bristol Myers Squibb...
(Date:10/6/2008)... LegalView recently posted detailed inform...he potentially serious side effects caused by the ... the drug,s potential side effects are the develop... for young adult and child patients. , ...- LegalView, the number one resource for everythin...
(Date:10/6/2008)... Hospital Ship Serving in West Africa Rece...Garden Valley, Texas October 6, 2008 -- www.seamob...l provider of communications services to remote lo...s to the FoxNews channel via satellite to Mercy Sh...ica Mercy. The Africa Mercy is the world,s larges...
Breaking Medicine News(10 mins):Health News:Plan Your Breasts in 3-D 2Health News:Global Sourcing Strategies for the Pharmaceutical Industry 10th - 11th November, Marriott Princeton, New Jersey USA 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 2Health News:LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis 3Health News:Seamobile Provides Foxnews To Mercy Ships 2Health News:Seamobile Provides Foxnews To Mercy Ships 3
... is not widely prescribed by the physicians to tho...tients with abnormal heart rhythm. They are less c...ates among them are the highest. In case of elders..., atrial fibrillation, are not prescribed warfarin...
... reducing the bad cholesterol. For example food li...anadian researchers said that by combining these f...ople should go in for such diet as they are at a h... These diets reduce the bad cholesterol (LDL) as e...
... a common feature in the hill state of Himachal Pr...t every year on an average//, with the gender rati...cking factor is that despite such unchecked preval... convicted so far. The hill state of Himachal Pra...
...spread of HIV/AIDS, that has been haunting Papua N...cided to contribute $34 million//. PNG has the hig.... The health minister, Dr Puka Temu who is worki... Prime Minister has welcomed the initiative. He fu...
Other Medicine News:Health News:Warfarin the Not So Popular Drug for Stroke 2Health News:Choose Foods That Keep Bad Cholesterol at Bay 2Health News:Female Ratio Drops Alarmingly In Himachal Due To Feticides 2
(Date:10/6/2008)...ay Eliminate 6 Weeks of Radiation Therapy -, Event...nternet Wednesday, October 22, 2008, 3 - 4 p.m.... , HAMPTON, Va., Oct. 6 / Questions ...sed with breast cancer in May. Would she have the,...ation or chemotherapy?, , To view the Multimedia...
(Date:10/3/2008)... Jersey is the newest study site, PHILADELPHIA, O...spital,of Philadelphia today received a contract t...,s Study. Children,s Hospital will manage local,pa...rlington County, New,Jersey. The study is funded b...rs anticipate approximately 1,000 families in Burl...
(Date:10/2/2008)...the Results of Rosetta Genomics, microRNA-based,Te...amous From non Squamous non Small Cell Lung C...ed on the miRview(TM) Technology First Approved fo...gh Complexity Molecular Pathology Lab ... is Expecting to Launch miRview(TM) Squamous Later...
(Date:10/2/2008)...RNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASD...company focused on,endocrine therapy and oncology,...ge of patient recruitment for its Phase 2 trial in...ne-releasing hormone (LHRH) agonist,linked to doxo... patient,recruitment was taken following recent fi...
Breaking Medicine Technology:Photos: Sentara Joins 4 U.S. Hospitals in International 'TARGIT' Breast Cancer Trial 2The Children's Hospital of Philadelphia Announces New Regional Participant in The National Children's Study 2Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 2Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 3Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 4Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 5AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 2AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 3AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 4AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108 5Evotec Expands Collaboration With InterMune 3744 1Evotec Expands Collaboration With InterMune 3744 2Evotec Expands Collaboration With InterMune 3744 3High levels of estrogen associated with breast cancer recurrence 2422 1High levels of estrogen associated with breast cancer recurrence 2422 2Secrets of cooperation between trees and fungi revealed 2419 1Secrets of cooperation between trees and fungi revealed 2419 2AHIP Statement on House Passage of Mental Health Parity Legislation 13613 1
...,s Oncology Group (COG) Study Presented at,America...HICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Im...used on developing monoclonal,antibodies to treat ... that treatment with epratuzumab plus standard,che...en with,B-precursor acute lymphoblastic leukemia (...
...t analyses of progression-free survival in,the SPA...ion in,relative risk of disease progression for pa...ded prior Taxotere use,geographies, as well as pr... /PRNewswire-FirstCall/ -- Pharmion,Corporation an...of,additional data from the double-blind, randomiz...
Other Medicine Technology:Promising Results with Epratuzumab and Chemotherapy in Children,with Acute Lymphoblastic Leukemia 2Promising Results with Epratuzumab and Chemotherapy in Children,with Acute Lymphoblastic Leukemia 3Promising Results with Epratuzumab and Chemotherapy in Children,with Acute Lymphoblastic Leukemia 4Promising Results with Epratuzumab and Chemotherapy in Children,with Acute Lymphoblastic Leukemia 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 2Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 3Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 6Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 7
...ed for continuous, random access operation, the El...rge volume laboratories that want to maximize prod...mplicity, flexibility and Stat capabilities of the...e changing needs of an aggressive laboratory testi...
The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t
Sample throughput of up to 80 tests per hour (4 modules). Low maintenance requirements. Continuous random access. 25 - 100 channels on board. 1008 tests or 6 hours of walkaway operation.
The Embla 96/384 well washer is a top-loading, robotic-compatible plate washer for 96- and 384-well microplate washing. It is ideal for ELISAs and most cell applications.
Medicine Products: